OEL Fastrac Catalog

Please note, this OEL/ADE monograph also applies to flecainide acetate (CAS RN 54143-56-5). Flecainide is a synthetic agent derived from trifluoroethoxy-benzamide exhibiting antiarrhythmic and local anesthetic activity. Flecainide is a class Ic antiarrhythmic agent used to manage and prevent supraventricular arrhythmias such as atrial fibrillation and paroxysmal supraventricular tachycardias (PSVT) as well as to prevent and treat pafroxysmal atrial arrhythmias (tachycardia, fibrillation and flutter) associated with disabling symptoms. Flecainide is also indicated for the prevention and treatment of severe symptomatic and life threatening ventricular arrhythmias such as paroxysmal ventricular arrhythmias and sustained ventricular tachycardia (VT). It is also indicated for the treatment of atrioventricular (AV) nodal reciprocating tachycardia, arrhythmias associated with Wolff-Parkinson-White syndrome, and similar conditions with accessory pathways when other treatment has been ineffective.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:

• The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
• A listing of all cited references utilized in the derivation of the OEL and ADE
• An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

• Fully documented. Over 20 pages in length, with calculations and cited references.
• Save time! Unsurpassed delivery with instant download.
• Save money. Similar documents cost 5-12 times as much.
• Stay current. Automatic notification of revisions.

How to order

To order an OEL/ADE monograph for Flecainide, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.